|
1
|
Wilson MS and Wynn TA: Pulmonary fibrosis:
pathogenesis, etiology and regulation. Mucosal Immunol. 2:103–121.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
du Bois RM: Strategies for treating
idiopathic pulmonary fibrosis. Nat Rev Drug Discov. 9:129–140.
2010. View
Article : Google Scholar : PubMed/NCBI
|
|
3
|
Wynn TA and Ramalingam TR: Mechanisms of
fibrosis: therapeutic translation for fibrotic disease. Nat Med.
18:1028–1040. 2012. View
Article : Google Scholar : PubMed/NCBI
|
|
4
|
Bringardner BD, Baran CP, Eubank TD and
Marsh CB: The role of inflammation in the pathogenesis of
idiopathic pulmonary fibrosis. Antioxid Redox Signal. 10:287–301.
2008. View Article : Google Scholar
|
|
5
|
Kliment CR and Oury TD: Oxidative stress,
extracellular matrix targets, and idiopathic pulmonary fibrosis.
Free Radic Biol Med. 49:707–717. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Fubini B and Hubbard A: Reactive oxygen
species (ROS) and reactive nitrogen species (RNS) generation by
silica in inflammation and fibrosis. Free Radic Biol Med.
34:1507–1516. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
No authors listed. Regulatory watch: First
drug for idiopathic pulmonary fibrosis approved in Japan. Nat Rev
Drug Discov. 7:966–967. 2008. View
Article : Google Scholar
|
|
8
|
Moran N: p38 kinase inhibitor approved for
idiopathic pulmonary fibrosis. Nat Biotechnol. 29:3012011.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Zhou L, Zuo Z and Chow MS: Danshen: an
overview of its chemistry, pharmacology, pharmacokinetics and
clinical use. J Clin Pharmacol. 45:1345–1359. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Chiu SC, Huang SY, Chen SP, Su CC, Chiu TL
and Pang CY: Tanshinone IIA inhibits human prostate cancer cells
growth by induction of endoplasmic reticulum stress in vitro and in
vivo. Prostate Cancer Prostatic Dis. 16:315–322. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Shan YF, Shen X, Xie YK, et al: Inhibitory
effects of tanshinone II-A on invasion and metastasis of human
colon carcinoma cells. Acta Pharmacol Sin. 30:1537–1542. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Yu T, Zhou Z, Mu Y, de Lima Lopes G and
Luo KQ: A novel anti-cancer agent, acetyltanshinone IIA, inhibits
oestrogen receptor positive breast cancer cell growth by
down-regulating the oestrogen receptor. Cancer Lett. 346:94–103.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Hong HJ, Liu JC, Cheng TH and Chan P:
Tanshinone IIA attenuates angiotensin II-induced apoptosis via Akt
pathway in neonatal rat cardiomyocytes. Acta Pharmacol Sin.
31:1569–1575. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Gao S, Liu Z, Li H, Little PJ, Liu P and
Xu S: Cardiovascular actions and therapeutic potential of
tanshinone IIA. Atherosclerosis. 220:3–10. 2012. View Article : Google Scholar
|
|
15
|
Chen Y, Wu X, Yu S, et al: Neuroprotection
of tanshinone IIA against cerebral ischemia/reperfusion injury
through inhibition of macrophage migration inhibitory factor in
rats. PLoS One. 7:e401652012. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Liu Y, Chen H and Jiang Y: Effect of
tanshinone IIA on CCl4-induced liver fibrosis in rats.
Zhong Yao Cai. 25:31–33. 2002.In Chinese.
|
|
17
|
Sun RF, Liu LX and Zhang HY: Effect of
tanshinone II on hepatic fibrosis in mice. Zhongguo Zhong Xi Yi Jie
He Za Zhi. 29:1012–1017. 2009.
|
|
18
|
Chunming J, Miao Z, Cheng S, et al:
Tanshinone IIA attenuates peritoneal fibrosis through inhibition of
fibrogenic growth factors expression in peritoneum in a peritoneal
dialysis rat model. Ren Fail. 33:355–362. 2011.In Chinese.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Walters DM and Kleeberger SR: Mouse models
of bleomycin-induced pulmonary fibrosis. Curr Protoc Pharmacol
Chapter. 5:462008.
|
|
20
|
Wu Z, Yang L, Cai L, et al: Detection of
epithelial to mesenchymal transition in airways of a bleomycin
induced pulmonary fibrosis model derived from an alpha-smooth
muscle actin-Cre transgenic mouse. Respir Res. 8:12007. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Ashcroft T, Simpson JM and Timbrell V:
Simple method of estimating severity of pulmonary fibrosis on a
numerical scale. J Clin Pathol. 41:467–470. 1988. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Hübner RH, Gitter W, El Mokhtari NE, et
al: Standardized quantification of pulmonary fibrosis in
histological samples. Biotechniques. 44:507–511. 514–507. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Savas HA, Gergerlioglu HS, Armutcu F, et
al: Elevated serum nitric oxide and superoxide dismutase in
euthymic bipolar patients: impact of past episodes. World J Biol
Psychiatry. 7:51–55. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Dongaonkar RM, Laine GA, Stewart RH and
Quick CM: Balance point characterization of interstitial fluid
volume regulation. Am J Physiol Regul Integr Comp Physiol.
297:R6–R16. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Cheresh P, Kim SJ, Tulasiram S and Kamp
DW: Oxidative stress and pulmonary fibrosis. Biochim Biophys Acta.
1832:1028–1040. 2013. View Article : Google Scholar :
|
|
26
|
Greenhough A, Smartt HJ, Moore AE, et al:
The COX‑2/PGE2 pathway: key roles in the hallmarks of cancer and
adaptation to the tumour microenvironment. Carcinogenesis.
30:377–386. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Gawel S, Wardas M, Niedworok E and Wardas
P: Malondialdehyde (MDA) as a lipid peroxidation marker. Wiad Lek.
57:453–455. 2004.In Polish.
|
|
28
|
Liu L, Lu W, Ma Z and Li Z: Oxymatrine
attenuates bleomycin-induced pulmonary fibrosis in mice via the
inhibition of inducible nitric oxide synthase expression and the
TGF-β/Smad signaling pathway. Int J Mol Med. 29:815–822.
2012.PubMed/NCBI
|
|
29
|
Song JS, Kang CM, Kang HH, et al:
Inhibitory effect of CXC chemokine receptor 4 antagonist AMD3100 on
bleomycin induced murine pulmonary fibrosis. Exp Mol Med.
42:465–472. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Chen YL, Zhang X, Bai J, et al: Sorafenib
ameliorates bleomycin-induced pulmonary fibrosis: potential roles
in the inhibition of epithelial mesenchymal transition and
fibroblast activation. Cell Death Dis. 4:e6652013. View Article : Google Scholar
|
|
31
|
Dong X, Dong J, Zhang R, Fan L, Liu L and
Wu G: Anti-inflammatory effects of tanshinone IIA on
radiation-induced microglia BV-2 cells inflammatory response.
Cancer Biother Radiopharm. 24:681–687. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Fan GW, Gao XM, Wang H, et al: The
anti-inflammatory activities of Tanshinone IIA, an active component
of TCM, are mediated by estrogen receptor activation and inhibition
of iNOS. J Steroid Biochem Mol Biol. 113:275–280. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Fang J, Xu SW, Wang P, et al: Tanshinone
II-A attenuates cardiac fibrosis and modulates collagen metabolism
in rats with renovascular hypertension. Phytomedicine. 18:58–64.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Kinnula VL, Fattman CL, Tan RJ and Oury
TD: Oxidative stress in pulmonary fibrosis: a possible role for
redox modulatory therapy. Am J Respir Crit Care Med. 172:417–422.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Todd NW, Luzina IG and Atamas SP:
Molecular and cellular mechanisms of pulmonary fibrosis.
Fibrogenesis Tissue Repair. 5:112012. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Chan P, Liu JC, Lin LJ, et al: Tanshinone
IIA inhibits angiotensin II-induced cell proliferation in rat
cardiac fibroblasts. Am J Chin Med. 39:381–394. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Zhang X, He D, Xu L and Ling S: Protective
effect of tanshinone IIA on rat kidneys during hypothermic
preservation. Mol Med Rep. 5:405–409. 2012.
|
|
38
|
Chiu TL and Su CC: Tanshinone IIA induces
apoptosis in human lung cancer A549 cells through the induction of
reactive oxygen species and decreasing the mitochondrial membrane
potential. Int J Mol Med. 25:231–236. 2010.PubMed/NCBI
|
|
39
|
Nielsen F, Mikkelsen BB, Nielsen JB,
Andersen HR and Grandjean P: Plasma malondialdehyde as biomarker
for oxidative stress: reference interval and effects of life-style
factors. Clin Chem. 43:1209–1214. 1997.PubMed/NCBI
|
|
40
|
Jeon SJ, Son KH, Kim YS, Choi YH and Kim
HP: Inhibition of prostaglandin and nitric oxide production in
lipopolysaccharide-treated RAW 264.7 cells by tanshinones from the
roots of Salvia miltiorrhizabunge. Arch Pharm Res. 31:758–763.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Sun D, Shen M, Li J, et al:
Cardioprotective effects of tanshinone IIA pretreatment via kinin
B2 receptor-Akt-GSK-3beta dependent pathway in experimental
diabetic cardiomyopathy. Cardiovasc Diabetol. 10:42011. View Article : Google Scholar
|
|
42
|
Dong K, Xu W, Yang J, Qiao H and Wu L:
Neuroprotective effects of Tanshinone IIA on permanent focal
cerebral ischemia in mice. Phytother Res. 23:608–613. 2009.
View Article : Google Scholar
|
|
43
|
Hsu YC, Wang LF and Chien YW: Nitric oxide
in the pathogenesis of diffuse pulmonary fibrosis. Free Radic Biol
Med. 42:599–607. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Genovese T, Cuzzocrea S, Di Paola R, et
al: Inhibition or knock out of inducible nitric oxide synthase
result in resistance to bleomycin-induced lung injury. Respir Res.
6:582005. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
hen TH, Hsu YT, Chen CH, Kao SH and Lee
HM: Tanshinone IIA from Salvia miltiorrhizainduces heme oxygenase-1
expression and inhibits lipopolysaccharide-induced nitric oxide
expression in RAW 264.7 cells. Mitochondrion. 7:101–105. 2007.
View Article : Google Scholar
|
|
46
|
Speyer CL, Neff TA, Warner RL, et al:
Regulatory effects of iNOS on acute lung inflammatory responses in
mice. Am J Pathol. 163:2319–2328. 2003. View Article : Google Scholar : PubMed/NCBI
|
